302.27 USD
+4.89 (+1.64%)
At close: Feb 6, 2026
302.28 USD
0.01 (0%)
After Hours: 2/6/2026, 8:25:39 PM
CME gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 238 industry peers in the Capital Markets industry. Both the profitability and the financial health of CME get a neutral evaluation. Nothing too spectacular is happening here. CME is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year CME was profitable.
- CME had a positive operating cash flow in the past year.
- CME had positive earnings in each of the past 5 years.
- Of the past 5 years CME 4 years had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 1.99%, CME is in line with its industry, outperforming 42.26% of the companies in the same industry.
- CME has a better Return On Equity (13.18%) than 72.80% of its industry peers.
- CME has a Return On Invested Capital of 18.56%. This is amongst the best in the industry. CME outperforms 94.56% of its industry peers.
- CME had an Average Return On Invested Capital over the past 3 years of 18.73%. This is significantly above the industry average of 7.27%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.99% | ||
| ROE | 13.18% | ||
| ROIC | 18.56% |
ROA(3y)2.34%
ROA(5y)1.97%
ROE(3y)13.02%
ROE(5y)11.7%
ROIC(3y)18.73%
ROIC(5y)14.69%
1.3 Margins
- With a decent Profit Margin value of 32.91%, CME is doing good in the industry, outperforming 79.50% of the companies in the same industry.
- CME's Profit Margin has declined in the last couple of years.
- CME has a better Operating Margin (80.16%) than 98.74% of its industry peers.
- CME's Operating Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 80.16% | ||
| PM (TTM) | 32.91% | ||
| GM | N/A |
OM growth 3Y4.02%
OM growth 5Y7.87%
PM growth 3Y-3.77%
PM growth 5Y-4.62%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for CME has been increased compared to 1 year ago.
- CME has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, CME has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 0.69, we must say that CME is in the distress zone and has some risk of bankruptcy.
- CME has a Altman-Z score (0.69) which is comparable to the rest of the industry.
- CME has a debt to FCF ratio of 0.85. This is a very positive value and a sign of high solvency as it would only need 0.85 years to pay back of all of its debts.
- The Debt to FCF ratio of CME (0.85) is better than 89.12% of its industry peers.
- CME has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
- CME's Debt to Equity ratio of 0.12 is fine compared to the rest of the industry. CME outperforms 78.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.85 | ||
| Altman-Z | 0.69 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 1.02 indicates that CME should not have too much problems paying its short term obligations.
- CME has a Current ratio (1.02) which is in line with its industry peers.
- CME has a Quick Ratio of 1.02. This is a normal value and indicates that CME is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.02, CME perfoms like the industry average, outperforming 46.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
- CME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.26%, which is quite good.
- Measured over the past years, CME shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.74% on average per year.
- CME shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.06%.
- The Revenue has been growing by 19.33% on average over the past years. This is quite good.
EPS 1Y (TTM)9.26%
EPS 3Y12%
EPS 5Y10.74%
EPS Q2Q%9.92%
Revenue 1Y (TTM)20.06%
Revenue growth 3Y19.31%
Revenue growth 5Y19.33%
Sales Q2Q%8.09%
3.2 Future
- The Earnings Per Share is expected to grow by 7.59% on average over the next years.
- Based on estimates for the next years, CME will show a small growth in Revenue. The Revenue will grow by 4.25% on average per year.
EPS Next Y5.6%
EPS Next 2Y5.94%
EPS Next 3Y6.61%
EPS Next 5Y7.59%
Revenue Next Year5.2%
Revenue Next 2Y5.41%
Revenue Next 3Y4.01%
Revenue Next 5Y4.25%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 26.96, which means the current valuation is very expensive for CME.
- Based on the Price/Earnings ratio, CME is valued a bit more expensive than 71.97% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.93. CME is around the same levels.
- The Price/Forward Earnings ratio is 25.53, which means the current valuation is very expensive for CME.
- Based on the Price/Forward Earnings ratio, CME is valued a bit more expensive than the industry average as 64.02% of the companies are valued more cheaply.
- CME's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.77.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.96 | ||
| Fwd PE | 25.53 |
4.2 Price Multiples
- 85.77% of the companies in the same industry are more expensive than CME, based on the Enterprise Value to EBITDA ratio.
- CME's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.69 | ||
| EV/EBITDA | 11.7 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CME does not grow enough to justify the current Price/Earnings ratio.
- CME has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)4.81
PEG (5Y)2.51
EPS Next 2Y5.94%
EPS Next 3Y6.61%
5. Dividend
5.1 Amount
- CME has a Yearly Dividend Yield of 1.68%. Purely for dividend investing, there may be better candidates out there.
- CME's Dividend Yield is comparable with the industry average which is at 6.13.
- Compared to an average S&P500 Dividend Yield of 1.81, CME has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.68% |
5.2 History
- The dividend of CME is nicely growing with an annual growth rate of 16.00%!
- CME has been paying a dividend for at least 10 years, so it has a reliable track record.
- CME has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)16%
Div Incr Years11
Div Non Decr Years11
5.3 Sustainability
- CME pays out 104.85% of its income as dividend. This is not a sustainable payout ratio.
- CME's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP104.85%
EPS Next 2Y5.94%
EPS Next 3Y6.61%
302.27
+4.89 (+1.64%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)02-04 2026-02-04/bmo
Earnings (Next)04-21 2026-04-21/bmo
Inst Owners91.62%
Inst Owner Change-2.15%
Ins Owners0.24%
Ins Owner Change-0.44%
Market Cap109.00B
Revenue(TTM)12.26B
Net Income(TTM)3.72B
Analysts70
Price Target297.93 (-1.44%)
Short Float %1.17%
Short Ratio2.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.68% |
Yearly Dividend9.97
Dividend Growth(5Y)16%
DP104.85%
Div Incr Years11
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.59%
Min EPS beat(2)0.43%
Max EPS beat(2)0.76%
EPS beat(4)3
Avg EPS beat(4)0.49%
Min EPS beat(4)-1.28%
Max EPS beat(4)2.05%
EPS beat(8)6
Avg EPS beat(8)0.72%
EPS beat(12)10
Avg EPS beat(12)0.95%
EPS beat(16)14
Avg EPS beat(16)1.13%
Revenue beat(2)0
Avg Revenue beat(2)-0.83%
Min Revenue beat(2)-1.11%
Max Revenue beat(2)-0.54%
Revenue beat(4)0
Avg Revenue beat(4)-0.98%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)-0.54%
Revenue beat(8)0
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)7.34%
Revenue beat(16)7
Avg Revenue beat(16)10.88%
PT rev (1m)2.15%
PT rev (3m)2.55%
EPS NQ rev (1m)0.93%
EPS NQ rev (3m)2.67%
EPS NY rev (1m)0.54%
EPS NY rev (3m)1.02%
Revenue NQ rev (1m)1.83%
Revenue NQ rev (3m)3.48%
Revenue NY rev (1m)0.67%
Revenue NY rev (3m)1.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.96 | ||
| Fwd PE | 25.53 | ||
| P/S | 9.65 | ||
| P/FCF | 26.69 | ||
| P/OCF | 26.19 | ||
| P/B | 3.87 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.7 |
EPS(TTM)11.21
EY3.71%
EPS(NY)11.84
Fwd EY3.92%
FCF(TTM)11.33
FCFY3.75%
OCF(TTM)11.54
OCFY3.82%
SpS31.32
BVpS78.18
TBVpS-6.01
PEG (NY)4.81
PEG (5Y)2.51
Graham Number140.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.99% | ||
| ROE | 13.18% | ||
| ROCE | 24.11% | ||
| ROIC | 18.56% | ||
| ROICexc | 19.93% | ||
| ROICexgc | 150.6% | ||
| OM | 80.16% | ||
| PM (TTM) | 32.91% | ||
| GM | N/A | ||
| FCFM | 36.16% |
ROA(3y)2.34%
ROA(5y)1.97%
ROE(3y)13.02%
ROE(5y)11.7%
ROIC(3y)18.73%
ROIC(5y)14.69%
ROICexc(3y)20.74%
ROICexc(5y)16.19%
ROICexgc(3y)290.88%
ROICexgc(5y)224.49%
ROCE(3y)24.31%
ROCE(5y)19.07%
ROICexgc growth 3Y16.89%
ROICexgc growth 5Y15.23%
ROICexc growth 3Y24.21%
ROICexc growth 5Y29.59%
OM growth 3Y4.02%
OM growth 5Y7.87%
PM growth 3Y-3.77%
PM growth 5Y-4.62%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.85 | ||
| Debt/EBITDA | 0.37 | ||
| Cap/Depr | 23.26% | ||
| Cap/Sales | 0.68% | ||
| Interest Coverage | 66.76 | ||
| Cash Conversion | 44.34% | ||
| Profit Quality | 109.88% | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | 0.69 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.26%
EPS 3Y12%
EPS 5Y10.74%
EPS Q2Q%9.92%
EPS Next Y5.6%
EPS Next 2Y5.94%
EPS Next 3Y6.61%
EPS Next 5Y7.59%
Revenue 1Y (TTM)20.06%
Revenue growth 3Y19.31%
Revenue growth 5Y19.33%
Sales Q2Q%8.09%
Revenue Next Year5.2%
Revenue Next 2Y5.41%
Revenue Next 3Y4.01%
Revenue Next 5Y4.25%
EBIT growth 1Y12.23%
EBIT growth 3Y24.1%
EBIT growth 5Y28.72%
EBIT Next Year8.7%
EBIT Next 3Y6.64%
EBIT Next 5Y6.53%
FCF growth 1Y12.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.95%
OCF growth 3YN/A
OCF growth 5YN/A
CME GROUP INC / CME FAQ
What is the ChartMill fundamental rating of CME GROUP INC (CME) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CME.
What is the valuation status of CME GROUP INC (CME) stock?
ChartMill assigns a valuation rating of 2 / 10 to CME GROUP INC (CME). This can be considered as Overvalued.
Can you provide the profitability details for CME GROUP INC?
CME GROUP INC (CME) has a profitability rating of 6 / 10.
What is the earnings growth outlook for CME GROUP INC?
The Earnings per Share (EPS) of CME GROUP INC (CME) is expected to grow by 5.6% in the next year.
Can you provide the dividend sustainability for CME stock?
The dividend rating of CME GROUP INC (CME) is 5 / 10 and the dividend payout ratio is 104.85%.